Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003881 · ClinicalTrials.gov registry record · Phase 2
Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003881 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group.
The verdict
NCT00003881, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of the monoclonal antibody trastuzumab plus carboplatin and paclitaxel in treating patients who have advanced non-small cell lung cancer.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- BIOLOGICAL trastuzumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-05 |
| Est. Completion | 2004-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003881
The ClinicalTrials.gov registry entry for NCT00003881 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00003881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003881 about?
NCT00003881 is a clinical study titled "Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy wi...
What is the current status of trial NCT00003881?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-05. Estimated completion is 2004-07.
What interventions are being tested in trial NCT00003881?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), trastuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003881?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.